Solid Biosciences has provided a full-year 2022 business update as well as details on the IGNITE DMD Phase I/II Clinical Study of SGT-001 for Duchenne muscular dystrophy. Highlights include:

• Solid’s acquisition of AavantiBio, creating a precision genetic medicines company with a focus on cardiac and neuromuscular diseases, including Duchenne.
• Data from the IGNITE DMD Phase I/II Clinical Study of SGT-001, which was closed and completed in April 2022, and plans for an Investigational New Drug (IND) submission for their next-generation gene therapy program, SGT-003, in the second half of 2023 and, pending IND acceptance, first patient dosing in late-2023.

We encourage you to read further details in their community letter below: